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BACKGROUND AND PURPOSE
Kyotorphin (KTP; L-Tyr-L-Arg), an endogenous neuropeptide, is potently analgesic when delivered directly to the central
nervous system. Its weak analgesic effects after systemic administration have been explained by inability to cross the
blood–brain barrier (BBB) and detract from the possible clinical use of KTP as an analgesic. In this study, we aimed to increase
the lipophilicity of KTP by amidation and to evaluate the analgesic efficacy of a new KTP derivative (KTP-amide – KTP-NH2).
EXPERIMENTAL APPROACH
We synthesized KTP-NH2. This peptide was given systemically to assess its ability to cross the BBB. A wide range of pain
models, including acute, sustained and chronic inflammatory and neuropathic pain, were used to characterize analgesic
efficacies of KTP-NH2. Binding to opioid receptors and toxicity were also measured.
KEY RESULTS
KTP-NH2, unlike its precursor KTP, was lipophilic and highly analgesic following systemic administration in several acute and
chronic pain models, without inducing toxic effects or affecting motor responses and blood pressure. Binding to opioid
receptors was minimal. KTP-NH2 inhibited nociceptive responses of spinal neurons. Its analgesic effects were prevented by
intrathecal or i.p. administration of naloxone.
CONCLUSIONS AND IMPLICATIONS
Amidation allowed KTP to show good analgesic ability after systemic delivery in acute and chronic pain models. The indirect
opioid-mediated actions of KTP-NH2 may explain why this compound retained its analgesic effects although the usual side
effects of opioids were absent, which is a desired feature in next-generation pain medications.
Abbreviations
BBB, blood–brain barrier; BOP, benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumfluorophosphate; CFA,
complete Freund’s adjuvant; DMF, N,N-dimethylformamide; HRMS-ESI, high-resolution mass spectra under electrospray
ionization; i.t., intrathecal; KTP, kyotorphin; KTP-NH2, kyotorphin-amide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; NMM, N-methylmorpholine; NOP, N/OFQ opioid receptor; PBS, phosphate-buffered
saline; SNI, spared nerve injury
Introduction
Kyotorphin (KTP; L-Tyr-L-Arg) was isolated from bovine brain
in 1979 (Takagi et al., 1979a,b) and has subsequently been
found in the brain of several mammals and in human cere-
brospinal fluid (Kolaeva et al., 2000). Later studies demon-
strated the analgesic activity of KTP in animal models, but
only following central delivery. KTP was 4.2-fold more potent
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than endogenous opioids, such as met-enkephalins, after
injection into the cisterna magna of mice (Shiomi et al.,
1981). However, only a brief activity at a high dose was
detected after systemic KTP administration (Chen et al.,
1998). The inability of KTP to cross the blood–brain barrier
(BBB) was proposed to explain these data and prevent any
putative clinical utility of this powerful analgesic.
KTP analgesia is reversed by naloxone, but the in vitro
binding to opioid receptors was found to be minimal
(Rackham et al., 1982). A distinct receptor for KTP was then
proposed (Ueda et al., 1986), having the dipeptide L-Leu-L-Arg
as antagonist (Ueda et al., 1989). Despite some experimental
evidence (Shiomi et al., 1981), such a specific KTP receptor has
never been identified. Furthermore, the flexibility of KTP
(Machuqueiro and Baptista, 2007) and the high activity of its
isomer L-Tyr-D-Arg also challenge the specific receptor
hypothesis. An alternative mechanism is a rapid degradation
of KTP, resulting in free L-Arg, the substrate for nitric oxide
(NO) synthase (Arima et al., 1997). The NO thus formed would
induce analgesia via met-enkephalin release, which is the
common final event leading to analgesia in both proposed
mechanisms. Whatever the details of the mechanism(s) of
action, it is clear that KTP can only become useful after
chemical modification to increase its ability to cross the BBB,
while preserving most of its structure and chemistry so that
the KTP derivative would remain effective and non-toxic.
We started to search for a KTP derivative with minimal
differences relative to KTP, but with improved capability to
interact with lipids, that is, more likely to cross the BBB. This
represented an apparent paradox, as the solubility of KTP in
aqueous media should be maintained, while lipid affinity
should be increased. This critical feature was the problem of a
recent KTP derivative (Lopes et al., 2006). Most of the previ-
ously published studies of KTP have used direct administration
to the central nervous system. However, from the point of view
of drug discovery, only those candidate compounds that are
active following systemic administration have pharmacologi-
cal relevance. Here, we focused on the potential of KTP-NH2 as
a new analgesic drug, and the effects, after systemic adminis-
tration, of this new compound were evaluated in several
experimental pain models. Furthermore, insights into the
mechanism of action were provided as well as indirect evi-
dence that points towards an increased ability to cross the BBB.
Methods
General synthetic procedures
The peptides were synthesized by a standard solution peptide
synthesis using Boc/tert-butyl strategy for the Tyr and
minimal side-chain protection (hydrochloride salt) for the
Arg-NH2 moieties. Each peptide was analysed for purity on
high-performance liquid chromatography (HPLC) and char-
acterized by proton nuclear magnetic resonance (1H-NMR)
and high-resolution mass spectra under electrospray ioniza-
tion (HRMS-ESI).
All commercially available chemicals were used as pur-
chased without further purification. Melting points (capillary
tube) were measured with an electrothermal digital melting
point apparatus IA 91000 and are uncorrected. 1H NMR spectra
were recorded on a Brucker DPX200 Advance spectrometer
(Bruker Biospin Corporation, Billerica, MA, USA) at 200 MHz.
Spectra recorded in CDCl3 were referenced to residual CHCl3 at
7.26 ppm. Spectra recorded in DMSO-d6 were referenced to
residual dimethyl sulphoxide (DMSO) at 2.49 ppm. Coupling
constants (J) are given in Hertz (Hz). The following abbrevia-
tions were used for spin multiplicity: s = singlet, d = doblet, t =
triplet, q = quarter, m = multiplet, dd = double doublet, bs =
broad singlet. HRMS were determined under conditions of ESI
on a Bucker MicroTof-Q instrument (Bruker Daltonics Inc.,
Billerica, MA, USA) using a lock-spray source.
HPLC analyses were carried out using a Dionex P680
instrument (Dionex Corporation, Sunnyvale, CA, USA). Sepa-
rations were achieved on an analytical C18 Kromasil reversed
phase column (4.6 mm ¥ 40 mm; 3.5 mm particle size). The
peptides were eluted using a linear gradient of 0–100%
CH3CN in 0.1% trifluoroacetic acid, at flow rate of
1.0 mL·min-1 over 7 min. The absorbance was measured at
220 nm. The HPLC retention time of each peptide was deter-
mined when the peak was at its maximum height. Analytical
thin layer chromatography (TLC) was performed on pre-
coated TLC plates, silica gel 60 F254 (Merck, Darmstadt,
Germany). The spots on the TLC plates were visualized with
UV/visible light (254 nm) and/or stained with a solution of
potassium permanganate (1.5 g/100 mL H2O).
Synthesis of KTP-NH2 (Tyr-Arg-NH2)
N-methylmorpholine (NMM) (3.3 mL, 30 mmol) was
added to a solution of Boc-Tyr(tBu)-OH (3.374 g, 10 mmol)
in N,N-dimethylformamide (DMF) (40 mL), and the
resulting mixture was stirred at room temperature for
1 h. Then, benzotriazole-1-yl-oxy-tris-(dimethylamino)-
phosphoniumfluorophosphate (BOP) (4.42 g, 10 mmol) and
H-Arg-NH2 2HCl (2.46 g, 10 mmol) were added. The resulting
reaction mixture was stirred overnight at room temperature.
Upon completion of the reaction (TLC monitoring), the reac-
tion mixture was filtered. The resulting solution was diluted
with ethyl acetate (100 mL) and washed with saturated
sodium bicarbonate (3 ¥ 50 mL), water (100 mL), 1 M
aqueous potassium hydrogen sulphate (3 ¥ 50 mL) and brine
(50 mL). The organic layer was dried over magnesium sul-
phate, filtered and concentrated in vacuo to afford compound
Boc-Tyr(tBu)-Arg-NH2 (2.7 g, 55% yield) as a colourless solid.
HPLC: tr (min) = 6.99. M.p. 123–125°C.1H NMR (DMSO-d6,
200 MHz) d 1.26 (s, 9H, C(CH3)3), 1.29 (s, 9H, C(CH3)3), 1.39–
1.78 [m, 4H (-CH2)2], 2.67 (dd, J = 14.0 Hz, J’ = 10.6 Hz, 1H of
the CH2-btyrosine), 2.94 (dd, J = 14.0 Hz, J’ = 3.6 Hz, 1H of the
CH2-btyrosine), 3.09 (q-apparent, J = 6.0 Hz, 2H, NHCH2), 4.01–
4.26 (m, 2H, CH-atyrosine and CH-aarginine), 6.85 (d, J = 8.4 Hz,
2H, CHaryl), 6.95 (bs, 1H, NH), 6.99 (bs, 1H, NH), 7.11 (bs, 3H,
NH), 7.15 (d, J = 8.4 Hz, 2H, CHaryl), 7.35 (bs, 1H, NH), 7.47 (t,
J = 6.0 Hz, 1H, NHCH2), 7.87 (d, J = 8.2 Hz, 1H, NH). HRMS
(ESI) m/z: calculated for C24H41N6O5 [M + H]+ 493.3138; found
493.3139. Boc-Tyr(tBu)-Arg-NH2 (2.6 g, 5.28 mmol) was dis-
solved in CH2Cl2 (8 mL), and the solution was cooled in an
ice bath. TFA (8 mL) was added dropwise, and the resulting
mixture was stirred at 0°C for 1–2 h. Upon completion of the
reaction (TLC monitoring), the solvent was removed under
reduced pressure. The resulting residue was triturated with
ether, collected and dried in vacuo. The resulting white solid
was dissolved in 1 M aqueous HCl and lyophilized. This
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process was repeated three times to afford Tyr-Arg-NH2
(1.76 g, 100% yield) as a hydrochloride salt. HPLC: tr (min) =
2.42. M.p. 80–83dec°C.1H NMR (DMSO-d6, 200 MHz) d 1.55–
1.82 [m, 4H (-CH2)2], 2.89 (dd, J = 14.4 Hz, J’ = 8.2 Hz, 1H of
the CH2-btyrosine), 3.06–3.23 (m, 2H, NHCH2 and 1H, of the
CH2-btyrosine), 4.09–4.14 (m, 1H, CH-atyrosine), 4.31–4.38 (m,
CH-aarginine), 6.80 (d, J = 8.4 Hz, 2H, CHaryl), 7.14 (d, J = 8.4 Hz,
2H, CHaryl), 7.25 (bs, 4H, NH), 7.51 (bs, 1H, NH), 7.77 (t, J =
5.6 Hz, 1H, NHCH2), 8.13 (bs, 3H, NH), 8.73 (d, J = 8.0 Hz, 1H,
NH). HRMS (ESI) m/z: calculated for C15H25N6O3 [M + H]+
337.1983; found 337.1975. Please see the supporting infor-
mation for details of the synthesis of KTP.
Animals
All animal care and experimental studies were in accordance
with the European Community Council Directive (86/609/
EEC) and the ethical guidelines for pain research in animals
(Zimmermann, 1983). Adult male Wistar rats (Charles River,
Lille, France), weighing between 270 and 310 g, were housed
in groups (two per cage) at temperature and light-controlled
conditions (22  2°C; lights on between 8 a.m. and 8 p.m.),
with free access to food and water. In order to induce habitu-
ation to the researcher and to minimize stress, the animals
used in the tail flick, hot plate and formalin tests were gently
handled daily in the test room and devices used to evaluate
pain responses, blood pressure or motor behaviour for 30 min
during the week that preceded the nociceptive tests and were
brought to the same room 1 h before the experiments. In the
chronic pain models (monoarthritis and spared nerve injury,
SNI), the rats were handled during 14 days after chronic pain
induction. The habituation protocols were previously shown
to minimize animal stress, by decreasing neuronal activation
in brain areas involved in stress and increase of adrenocorti-
cotropic hormone synthesis (Pan et al., 1997). For all experi-
mental groups, group size was 6.
Administration of compounds
All administered compounds were dissolved in saline (inject-
able solution of sodium chloride, 0.9%, from Labesfal,
Lisboa, Portugal). Doses were adapted to animals’ weight,
and the injected volume was kept below 350 mL. The gavage
technique was used for oral administrations. Animals were
very lightly sedated (isoflurane volatile anaesthesia for
1 min) and intubated with a gastric probe (5 cm length, Fine
Science Tools 18061-15, Fine Science Tools Inc., Heidelberg,
Germany). After drug delivery into the stomach, the probe
was slowly removed. For intrathecal (i.t.) administration of
naloxone (Sigma, Lisboa, Portugal), i.t. catheters were
implanted into the lumbar subarachnoid space at the L6
spinal cord level under a mixture of ketamine hydrochloride
(Ketalar, 0.06 g·kg-1) and medetomidine (Domitor,
0.25 g·kg-1) given intraperitoneally (i.p.). Animals were
allowed to recover from surgery for 3 days.
For the experiments involving morphine administration
(Labesfal), this analgesic was given in a dose of 5 mg·kg-1 for
the acute pain experiments (tail flick and hot plate tests) and
6 mg·kg-1 for chronic pain models (monoarthritis and neuro-
pathic pain). Naloxone was injected i.t. (10 mL; 5 mg·mL-1) or
i.p. (5 mg·kg-1), and 10 min later, the peptides or saline were
injected i.p.
Models of acute pain
The tail flick test was performed as described previously
(D’Amour and Smith, 1941). A radiant heat (infrared) source
adjusted to 10 W of a tail flick apparatus (mod. 7360, Ugo
Basile, Comerio, Italy) was directed to the ventral surface of
the rat’s tail. Three trials were performed at each time point in
three different parts of the tail (3–5 cm from its tip). The time
(in s) required to remove the tail from the heat stimulus was
recorded. The tail flick latency was defined as the mean of the
three trials. To avoid tissue damage, a cut-off time of 24 s was
used. For the hot plate test, a similar procedure was used, but
thermal responses were evaluated at the hind paw using the
hot plate apparatus (IITC Life Sciences Analgesimeter, San
Fernando Valley, CA, USA). The animals were placed in a
plexiglass box (12 cm diameter; 22.5 cm height) on a metal
surface. The initial temperature was 35°C, and an increasing
rate temperature of 9°C per minute was defined. The tempera-
ture (in °C) to elicit a hind paw shake was recorded. A cut-off
temperature of 52.5°C was defined. In both behavioural tests,
the animals were evaluated before KTP, KTP-NH2, morphine or
saline drug injection (basal values) and 15, 30, 45, 60 and
90 min after i.p. injections. The behavioural evaluation was
extended to 120 min in the case of oral administration. The
responses are shown as the difference between values at each
time after treatment and the basal values (zero time).
Models of inflammatory and
neuropathic pain
The formalin test was performed as described previously
(Tjolsen et al., 1992). The animals were injected i.p. with each
peptide (32.3 mg·kg-1) or with the same volume of saline. Ten
minutes later, 50 mL of 5% neutral formalin was injected s.c.
into the dorsal surface of the left hind paw with a 30 G
needle. After formalin injection, the rats were placed indi-
vidually in an open Plexiglas chamber (10 ¥ 20 ¥ 24 cm), and
their behaviour was recorded during 60 min. The recordings
were analysed using a purpose-made computer programme
(Ottoni, 2000). Data are presented as the number of jerks/
flinches (named here as paw jerks) of the injected hind paw in
12 successive periods of 5 min each. The animals were killed
2 h after formalin injection for the analysis of c-fos activa-
tion, since this is considered the time point of maximal
expression of the proto-oncogene (Coggeshall, 2005).
Chronic inflammation (monoarthritis) was induced by
injecting the left tibiotarsal joint with 50 mL of a complete
Freund’s adjuvant (CFA) solution prepared as described pre-
viously (Butler et al., 1992), under brief isoflurane anaesthesia
(5%; Abbott Laboratories, Amadora, Portugal). After the intra-
articular injection, the animals returned to their cages and
continued to be handled daily for 14 days for habituation
purposes. Thermal nociceptive thresholds were assessed using
the radiant-heat paw withdrawal test, as described previously
(Butler et al., 1992). Briefly, the inflamed hind paw received a
light beam from the tail flick device referred above, and the
time (in seconds) the animal took to remove the paw from
the stimulus was recorded. The test was performed three
times, and the average value was taken as the paw withdraw
latency. Cut-off value was defined at 24 s. The test was per-
formed before peptide injection (32.3 mg·kg-1), morphine
(6 mg·kg-1) or saline (baseline values) and 15, 30, 45, 60 and
90 min following administration.
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An experimental neuropathy was induced using the SNI
model, as originally described (Decosterd and Woolf, 2000).
Fourteen days after surgery, animals were i.p. injected with
32.3 mg·kg-1 of KTP-NH2, KTP or with the same volume of
saline. Nociceptive responses before peptide injection and 30,
60 and 90 min later were collected. Standard tests aimed at
assessing mechanical allodynia, cold allodynia and mechani-
cal hyperalgesia were performed by stimulating the lateral
plantar surface of the injured hind paw (Decosterd and
Woolf, 2000). Mechanical allodynia was assessed with a set of
von Frey monofilaments (Somedic, Horby, Sweden) applied
in a sequence of increasing forces. The threshold was consid-
ered the lowest force that evoked a brisk withdrawal response
to at least one out of five stimuli. Cold allodynia was deter-
mined by the application of a drop of acetone and by record-
ing the duration of the withdrawal response, with a minimal
value of 0.5 s. Mechanical hyperalgesia was determined using
the pin prick test, which consists of a brief stimulation with
a safety pin at intensity sufficient to indent the skin. The
duration of the paw withdrawal was recorded with an arbi-
trary minimal time of 0.5 s. Additionally, a chronic treatment
regimen (daily administration of 32.3 mg·kg-1 for 7 days) was
used. Following the seventh injection, the animals were
evaluated for the same three sensory modalities. For compari-
son, in the SNI model, animals received one single adminis-
tration of morphine (6 mg·kg-1) and were also tested for
mechanical allodynia, cold allodynia and mechanical
hyperalgesia.
Immunostaining for Fos
Two hours after formalin injection, the animals were tran-
scardially perfused with 200 mL of phosphate-buffered saline
(PBS), followed by 1000 mL of 4% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.4. Spinal cord segments L4-L5 were
removed and post-fixed by immersion for 3 h in fixative.
After overnight cryoprotection, at 4°C, in a 30% sucrose solu-
tion in 0.1 M PBS, coronal sections (40 mm thick) were cut on
a freezing microtome and collected in PBS. One in every three
sections obtained from the spinal cord was immunostained
for Fos, the protein produced upon c-fos activation, by incu-
bating overnight with a rabbit anti-Fos polyclonal antibody
(Ab5, Oncogene, Munich, Germany), at 1:10 000, at room
temperature. To decrease background staining, incubation in
primary antiserum was preceded by immersion for 2 h in
0.1 M glycine and 10% normal swine serum diluted in a PBS
solution containing 0.3% Triton X-100 (PBST). Following
repeated washing in PBST, sections were incubated in bioti-
nylated swine anti-rabbit antibody (Dako, Glostrup,
Denmark) followed by an ABC solution (Vectorstain Elite,
Vector, Burlingame, CA, USA), both for 1 h at 1:200. The DAB
chromogen was used (Tavares et al., 1997), and the sections
were mounted on gelatin-coated slides, cleared in xylol and
coverslipped with Eukitt. Additional spinal sections immune-
stained for Fos were counterstained with formol–thionin in
order to delimit the spinal dorsal horn (Pinto et al., 2003).
Neurons immunoreactive for Fos were counted in the spinal
dorsal horn (laminae I–VI) when the immunoreaction for Fos
protein was expressed at the nucleus, independently of the
staining intensity (Coggeshall, 2005). Mean numbers of Fos-
immunoreactive neurons per section were calculated.
In vitro opioid receptor binding
Opioid receptor binding studies were performed by CEREP©,
study number 19074. Competitive binding to opioid
receptors – human d2, k, human m and the N/OFQ (NOP)
receptors – in the presence of radioligands [3H]DADLE,
0.5 nM; [3H]U 69593, 1 nM; [3H]DAMGO, 0.5 nM and [3H]no-
ciceptin, 0.2 nM, respectively, were performed with 150 mM
KTP-NH2 and detected by scintillation counting. The source
of d and k opioid receptors were CHO cells and that for m
opioid and NOP receptors were HEK-293 cells. Receptor
nomenclature follows Alexander et al. (2009).
Statistical analyses
Data are represented as the group means  SEM. The signifi-
cance of differences in each group was analyzed with
Friedman’s-test followed by Dunn’s multiple comparison
test. The significance of differences for each dose and time
point compared with the KTP-treated controls was analysed
with non-parametric two-tailed Mann–Whitney test. All sta-
tistical analyses were calculated with Prism software (Graph-
Pad Software, version 5, La Jolla, CA, USA).
Results
KTP-NH2 analgesia in acute pain models
The analgesic effects of KTP-NH2 were evaluated after i.p. or
oral administrations to male Wistar rats. As it is derived from
KTP, the doses of KTP-NH2 were based on previous studies
using intracisternal injections of KTP (Takagi et al., 1979a,b)
and increasing the concentration by about 250-fold for sys-
temic delivery. Following i.p. administration, and unlike the
original KTP, a dose- and time-dependent inhibition was
detected both in the tail flick and hot plate tests (Figure 1A,
B). With the exception of the lower dose (16.7 mg·kg-1), sta-
tistically significant increases of response thresholds were
obtained with all the KTP-NH2 doses tested. A comparison of
the analgesic effects of KTP-NH2 and morphine (Figure 1A, B)
showed that the equi-effective dose of KTP-NH2 was about
fivefold that of morphine, in terms of mg/kg. In molar terms,
for KTP-NH2, 32.3 mg·kg-1 = 96 mmol·kg-1 and for morphine,
5 mg·kg-1 = 17.5 mmol·kg-1. However, whereas KTP-NH2
induced no detectable side effects on blood pressure (Fig-
ure S1), basal temperature or motor performance (Figure S2),
morphine appears to induce motor impairment (Patti et al.,
2005). Oral administration studies confirmed the analgesic
efficacy of KTP-NH2 in the tail flick and hot plate tests
(Figure 1C, D). Both the 161 mg·kg-1 and the 200 mg·kg-1
dose also induced a long-lasting inhibition in the tail flick
and hot plate tests that lasted until the end of the evaluation
period (2 h). No analgesic effects were obtained after i.p. or
oral administration of non-amidated KTP (Figure 1A–D) or
after saline injections (Figure 1A, B).
Inhibition of nociceptive transmission
following KTP-NH2 administration
In order to increase pharmacological relevance, we proceeded
to investigate the effects of KTP-NH2 in a model of sustained
pain, the formalin test, characterized by two distinct pain
BJPKyotorphin-amide: a new analgesic peptide
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Figure 1
Analgesic profile of KTP-NH2. Analgesia was induced in the tail flick (A,C), hot plate (B,D) and formalin (E) tests after i.p. (A, B, E) or oral (C, D)
administration. (A–D) Results expressed as the change in the behavioural responses at each evaluation time point, relative to baseline values (time
0) obtained immediately before injection. The analgesic effects were dose-dependent, starting at 15 min and lasting at least for 30 min. In the
formalin test (E), the analgesic effects of an i.p. injection of KTP-NH2 (32.3 mg·kg-1) 10 min before formalin injection were detected in the acute
(t < 10 min) and inflammatory (t > 10 min) phases. In panel (F), nociceptive activation of spinal neurons induced by formalin was inhibited by
KTP-NH2, as indicated by the lower number of Fos-immunoreactive neurons at the spinal dorsal horn, laminae I–VI, relatively to KTP- or
saline-treated animals. Doses shown as mg·kg-1. Data shown are means  SEM; for all groups n  6. *P < 0.05; **P < 0.01; ***P < 0.001 versus
basal response, Friedman test, and #P < 0.05, ##P < 0.01, ###P < 0.001 versus KTP-treated controls, Mann–Whitney test. KTP, kyotorphin.
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phases: acute (t < 10 min) and sustained–chronic (t > 10 min).
Based on the time course of the effects of the compound in
the acute pain tests, KTP-NH2 was given i.p. 10 min before
formalin at a dose of 32.3 mg·kg-1. Animals injected with
non-amidated KTP (at this dose) or saline showed a pattern of
behavioural responses very similar to that of animals injected
only with formalin (Figure 1E) (Dubuisson and Dennis,
1977). By contrast, after injection of KTP-NH2, a significant
reduction of paw jerks was detected both in the acute and
sustained phases of the test, when compared to KTP or saline-
treated groups (Figure 1E). The nociceptive activation of
spinal dorsal horn neurons laminae I–VI in formalin-injected
rats was assessed using immunodetection of the Fos protein,
a standard method to evaluate nociceptive activation of neu-
ronal populations at the spinal cord (Pinto et al., 2003). The
number of Fos-immunoreactive neurons was lower in the
dorsal horn of animals treated with KTP-NH2 (Figure 1F).
The higher inhibition of the second phase of the formalin test
(Figure 1E), along with the decrease of nociceptive activation
induced by KTP-NH2 (Figure 1F), reveals central inhibition of
nociceptive transmission.
Efficacy of KTP-NH2 in chronic pain
animal models
We next investigated the efficacy of KTP-NH2 in animal
models of chronic pain (inflammatory or neuropathic). In the
chronic inflammatory pain model – monoarthritis – KTP-NH2
at the dose of 32.3 mg·kg-1 significantly increased the thresh-
old response (Figure 2A), with a profile of action similar to
that obtained with acute stimulus. This figure also shows that
KTP appeared to decrease withdrawal latencies. This phenom-
enon was also observed for saline treated animals. Over time,
there is an apparent increase in hypersensitivity on the
injured paw of the animal. However, none of these effects
were statistically significant.
The SNI model was selected as the model for neuropathic
pain. Before the induction of SNI, the animals responded to
the 26 g filament in the von Frey test and did not exhibit any
behavioural response in the pin-prick or acetone tests, in a
manner similar to previous studies (Decosterd and Woolf,
2000; Martins et al., 2010). After the SNI model of neuro-
pathic pain had reached a stable level, a single administration
of KTP-NH2 elicited no analgesic effects on the three behav-
ioural tests namely the von Frey (Figure 2B), pin prick
(Figure 2C) and acetone (Figure 2D). However, after chronic
treatment with KTP-NH2, clear effects were observed. After
seven daily injections of KTP-NH2 at 32.3 mg·kg-1, mechani-
cal allodynia (Figure 2E), mechanical hyperalgesia (Figure 2F)
and cold allodynia (Figure 2G) were all reversed. This signifi-
cant analgesia on the three sensory modalities evaluated
demonstrated that KTP-NH2 did not induce tolerance. For
KTP, and in accordance with the previous results, animals
treated for 7 days with the same dose (32.3 mg·kg-1, daily) did
not display any inhibition of nociception (Figure 2E–G). In
the same model, a single injection of morphine elicited anti-
nociception (Figure 2B–D).
Possible opioidergic effects of KTP-NH2
To study the mechanisms of action of KTP-NH2, the animals
received i.p. or i.t. injections of naloxone (i.p. 5 mg·kg-1 and
i.t. 10 mL; 5 mg·mL-1), 10 min before the i.p. injection of
KTP-NH2 (32.3 mg·kg-1), and the effects were evaluated in the
tail-flick (Figure 3A, C) and hot-plate tests (Figure 3B, D).
Regardless of the route of administration of naloxone, the
analgesic effects of KTP-NH2 were reversed in both behav-
ioural tests (Figure 3A–D).
In order to further understand the involvement of opioid
mechanisms in KTP-NH2 mode of action, in vitro binding
studies for opioid receptors were performed for d, k, m opioid
receptors and the NOP receptor. The percentage of inhibition
of control specific binding was 30, 52, 58 and 11, respectively,
for a relatively high concentration of KTP-NH2 – 150 mM.
Although not completely absent, the affinity of KTP-NH2 for
opioid receptors was rather weak.
Toxicological evaluation
Toxicological assessments performed after seven daily
injections of KTP-NH2 (32.3 mg·kg-1) did not show any
histological signs of damage in the liver, kidney or spleen,
nor changes in enzymic assays of the hepatic function or
antioxidant activity in blood plasma (Table S1). In addition,
three standard in vitro cell viability assays – Trypan blue,
Crystal Violet and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay – were performed using
three mammalian cell lines: HeLa, Huh-7 and V-79 hamster
fibroblasts. For all nine combinations, KTP-NH2 concentra-
tions up to 1000 mM yielded similar results: cytotoxicity was
nearly absent (Table S2).
Discussion and conclusions
Amidation proved to be a simple and inexpensive modifica-
tion that converted kyotorphin into an effective and safe
analgesic molecule, very likely able to cross the BBB. Using
systemic administration and a wide range of in vivo pain
models, we showed that KTP-NH2 was an effective analgesic,
with high activity in all the models tested. Thus, derivatiza-
tion maintained the analgesic potential after systemic admin-
istration. Both oral and i.p. injections of KTP-NH2 succeeded
in inducing anti-nociception in two acute pain behavioural
tests. The doses required to induce analgesia after i.p. admin-
istration were lower than those required after oral delivery, by
about sixfold, probably due to peptidase degradation in the
gastrointestinal tract (Haseto et al., 1994). Furthermore, the
results suggested that KTP-NH2 was able to cross the BBB,
which may result from an increase in lipophilicity caused by
the transformation of the carboxyterminal of the peptide.
Central effects are likely to be involved in the analgesic
actions of KTP-NH2, as nociceptive activation of the spinal
dorsal horn was reversed by KTP-NH2 administration, and
this analgesic action was blocked by i.t. delivery of naloxone.
In spite of their differences in the route of effective
administration, KTP-NH2 and KTP differ structurally only by
the amidation. The present study shown that the analgesic
action of KTP-NH2 was reversed by the non-specific opioid
receptor antagonist naloxone, and that direct binding of KTP-
NH2 to opioid receptors was absent or very weak. Similar
results were obtained with the original KTP molecule
(Rackham et al., 1982). Additionally, we observed that
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Figure 2
KTP-NH2 suppresses pain behaviour in animal models of chronic pain. (A) KTP-NH2 (32.3 mg·kg-1) significantly increased the threshold response
in the monoarthritic model. In the neuropathic pain model (B–G), the administration of a single dose of KTP-NH2 did not induce significant effects
(B–D). Daily treatment with KTP-NH2 for 7 days provoked an increase of the weight threshold at 30 min for Von-Frey test (E). In the pin prick (F)
and acetone tests (G), a significant decrease of the time of protection was detected 30 min after KTP-NH2 injection. Results are expressed as the
change in the behavioural responses of each animal along the course of the experiments. Baseline values (time 0) were obtained immediately
before KTP-NH2 injection. Doses shown as mg·kg-1. Data shown are means  SEM; for all groups n  6. *P < 0.05; **P < 0.01; ***P < 0.001 versus
basal response, Friedman test, and #P < 0.05, ##P < 0.01, ###P < 0.001 versus KTP-treated controls, Mann–Whitney test. KTP, kyotorphin.
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KTP-NH2 retained its high analgesic efficacy without the side
effects of opioids, which is a desired feature in next-
generation pain medications. No effects were detected as to
motor capacities, blood pressure or tolerance after KTP-NH2
administration. Even after 7 days of daily injection, KTP-NH2
was still analgesic in the SNI neuropathic pain model, which
does not occur with similar chronic injections of morphine,
as its analgesic efficacy disappears, indicating the develop-
ment of tolerance (Rougeot et al., 2010). Collectively, our
data suggested that opioid pathways are somehow involved
in KTP-NH2 activity, although the binding appears to be
indirect. Molecularly, morphine interacts preferably with
cholesterol-rich membranes (Huidobro-Toro et al., 1976),
where opioid receptors are mainly concentrated (Xu et al.,
2006). Our preliminary data regarding KTP-NH2 interaction
with membrane model systems indicates a preference of this
molecule for fluid, negatively charged, membranes (Fig-
ure S3), which indicates different profiles of interaction for
these two compounds (morphine and KTP-NH2)and supports
the hypothesis of distinct molecular modes of action. There-
fore, these results suggest that KTP-NH2 may act by the same
mechanisms demonstrated for KTP, namely, rapid degrada-
tion of KTP-NH2, resulting in the release of L-Arg, the sub-
strate for NO synthase, which would then induce analgesia
via met-enkephalin release (Arima et al., 1997). Indirect
opioid actions may therefore explain the analgesic effects of
KTP-NH2. Drug discovery groups in both academia and indus-
try are struggling to find new pain relieving drugs. As the
number of people suffering from pain keeps increasing, few
novel molecular entities to fight pain have entered the clinic
in the past 50 years, despite the increasing pharmaceutical
investment (Woodcock et al., 2007; Melzack, 2008; Kissin,
2010). The remarkable feature about this new peptide, KTP-
NH2, is its efficacy in several clinically relevant pain models.
There are very few compounds effective in such a broad range
of clinical situations. This clearly shows that KTP-NH2 has
pharmacological interest for clinical development. Indeed, a
patent on the application of KTP-NH2 for the treatment of
pain has been already licensed (WO2009/123487 A1).
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Figure 3
Naloxone reverses analgesia induced by KTP-NH2 in tail flick and hot plate tests. A reversal of KTP-NH2 (32.3 mg·kg-1)-induced analgesia occurred
after i.p. (A, B) and i.t. (C, D) administration of naloxone (Nlx; i.p. 5 mg·kg-1 and i.t. 10 mL; 5 mg·mL-1) in tail flick (A, C) and hot plate (B, D)
tests. Results are expressed as the change in the behavioural responses at 30 min relative to baseline values. Data shown are means  SEM; for
all groups n  6. ##P < 0.01, ###P < 0.001 versus KTP-treated controls, Mann–Whitney test. (Note: in panel B, # P = 0.05). KTP, kyotorphin.
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